ArticleCellular oncology (Dordrecht, Netherlands)2026
Protein phosphatase 2 phosphatase activator (PTPA) promotes oncogene-induced senescence and carboplatin response in human malignant pleural mesothelioma cells.
Article in Cellular oncology (Dordrecht, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
purposeMalignant pleural mesothelioma (MPM) is a rare cancer of the pleura, frequently related to asbestos exposure. It is characterized by a grim prognosis, as few therapeutic options are available. Typically, MPM exhibits high molecular heterogeneity, providing opportunities for exploiting therapeutic vulnerabilities in well-defined subgroups of patients. Nevertheless, these options have been insufficiently explored. METHODS &
resultsWe found that inactivation of Protein Phosphatase 2A (PP2A) is a recurrent event in MPM, affecting the cancer cell phenotype and chemotherapy response. Specifically, in silico analysis showed that heterozygous loss of PTPA (PPP2R4), encoding the PP2A activator PTPA, occurred in 26% of MPM patients (TCGA, n = 87), correlating with significantly decreased overall survival. Re-expression of PTPA in PTPA-low human MPM cells decreased 2D colony formation and anchorage-independent cell growth, without affecting cell migration. At enzyme level, PTPA restoration increased PP2A catalytic subunit expression and activity (methylation), without favoring specific PP2A holoenzymes. Comparative RNAseq and Gene Set Enrichment Analysis revealed increased RAS pathway activation, activated p53 signaling and induction of senescence (SA-β-Galactosidase, SASP, NF-κB activation) upon PTPA restoration, presumably by increased PP2A-dependent dephosphorylation of Kinase Suppressor of Ras 1. Suppressing Ras signaling by Trametinib (MEK-inhibitor) prevented senescence induction, and pretreatment with senolytic agents restored impaired growth. ATUX-792, a pharmacologic PP2A activator, did not phenocopy senescence induction. Finally, PTPA restoration sensitized MPM cells to carboplatin as the likely consequence of lethal stress induction.
conclusionsPTPA promotes oncogene-induced senescence (OIS) in MPM. By preventing OIS, heterozygous PTPA loss may contribute to mesothelial transformation and carboplatin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.